Pulmatrix Appoints New CMO, Elects Director
Ticker: PULM · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1574235
Sentiment: neutral
Topics: management-change, board-election, compensation
TL;DR
Pulmatrix shakes up leadership with a new CMO and board member, plus new pay deals for execs.
AI Summary
Pulmatrix, Inc. announced on March 7, 2024, the appointment of Dr. David Lee as Chief Medical Officer and the election of Ms. Sarah Johnson to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, including base salaries and potential bonuses, effective March 7, 2024.
Why It Matters
These executive and board changes could signal a shift in the company's strategic direction or operational focus, potentially impacting its future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key leadership and executive compensation can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Pulmatrix, Inc. (company) — Registrant
- Dr. David Lee (person) — Appointed Chief Medical Officer
- Ms. Sarah Johnson (person) — Elected to Board of Directors
- March 7, 2024 (date) — Effective date of appointments and compensation arrangements
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. David Lee has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Sarah Johnson has been elected to the Board of Directors.
What is the effective date of these changes?
The effective date of these changes is March 7, 2024.
What other information is disclosed regarding executive compensation?
The filing discloses compensatory arrangements for certain officers, including base salaries and potential bonuses.
What is the principal executive office address for Pulmatrix, Inc.?
The principal executive office is located at 36 Crosby Drive, Suite 100, Bedford, MA 01730.
Filing Stats: 483 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-03-13 06:03:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PULM The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 35KB
- 0001493152-24-009751.txt ( ) — 203KB
- pulm-20240307.xsd (EX-101.SCH) — 3KB
- pulm-20240307_lab.xml (EX-101.LAB) — 33KB
- pulm-20240307_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PULMATRIX, INC. Date: March 13, 2024 By: /s/ Teofilo Raad Teofilo Raad Chief Executive Officer